48
Participants
Start Date
July 16, 2025
Primary Completion Date
March 31, 2028
Study Completion Date
March 31, 2028
Fecal microbiota transfer
FMT via capsule (50 g of fecal matter) on day 0 and day 21.
Vancomycin Oral Capsule
Vancomycin orally (250 mg 4xd, day -3 to 0).
Atezolizumab + Bevacizumab
Atezolizumab 1200mg i.v. \& Bevacizumab 15mg/kg body weight i.v. (A/B) as standard of care (SOC).
Placebo Vancomycin Oral Capsule
Placebo Vancomycin orally (4xd, day -3 to 0).
Placebo Fecal microbiota transfer
Placebo Fecal microbiota transfer (FMT) via capsule on day 0 and day 21.
NOT_YET_RECRUITING
University Hospital Essen, Essen
NOT_YET_RECRUITING
University Hospital Mannheim, Mannheim
RECRUITING
University Hospital Heidelberg, Heidelberg
NOT_YET_RECRUITING
University Hospital Tübingen, Tübingen
NOT_YET_RECRUITING
University Hospital Augsburg, Augsburg
NOT_YET_RECRUITING
University Hospital Ulm, Ulm
NOT_YET_RECRUITING
University Hospital Regensburg, Regensburg
National Center for Tumor Diseases, Heidelberg
OTHER
German Cancer Research Center
OTHER
Heidelberg University
OTHER
University of Cologne
OTHER
Universitätsmedizin Mannheim
OTHER
Michael Dill
OTHER